Lisanti Capital Growth LLC Sells 14,485 Shares of RxSight, Inc. (NASDAQ:RXST)

Lisanti Capital Growth LLC trimmed its position in RxSight, Inc. (NASDAQ:RXST) by 13.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,335 shares of the company’s stock after selling 14,485 shares during the period. Lisanti Capital Growth LLC owned approximately 0.26% of RxSight worth $4,969,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of RxSight by 21.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,433,953 shares of the company’s stock worth $39,993,000 after buying an additional 255,150 shares during the last quarter. Great Lakes Advisors LLC purchased a new position in RxSight in the fourth quarter valued at approximately $8,226,000. Victory Capital Management Inc. lifted its stake in RxSight by 108.6% in the fourth quarter. Victory Capital Management Inc. now owns 256,684 shares of the company’s stock valued at $10,349,000 after purchasing an additional 133,642 shares during the last quarter. Parkman Healthcare Partners LLC lifted its stake in RxSight by 34.5% in the fourth quarter. Parkman Healthcare Partners LLC now owns 513,032 shares of the company’s stock valued at $20,685,000 after purchasing an additional 131,701 shares during the last quarter. Finally, Capstone Investment Advisors LLC lifted its stake in RxSight by 698.4% in the first quarter. Capstone Investment Advisors LLC now owns 127,200 shares of the company’s stock valued at $6,561,000 after purchasing an additional 111,269 shares during the last quarter. 78.78% of the stock is owned by institutional investors.

Insider Transactions at RxSight

In other news, CFO Shelley B. Thunen sold 10,000 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $58.61, for a total transaction of $586,100.00. Following the completion of the sale, the chief financial officer now directly owns 13,938 shares in the company, valued at $816,906.18. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CFO Shelley B. Thunen sold 10,000 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $58.61, for a total transaction of $586,100.00. Following the completion of the sale, the chief financial officer now directly owns 13,938 shares in the company, valued at $816,906.18. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Ronald M. Md Kurtz sold 40,000 shares of the stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $60.15, for a total transaction of $2,406,000.00. Following the sale, the chief executive officer now owns 764,610 shares of the company’s stock, valued at $45,991,291.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 75,625 shares of company stock worth $4,425,250. Company insiders own 9.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Wells Fargo & Company upped their price objective on RxSight from $61.00 to $68.00 and gave the company an “overweight” rating in a research note on Tuesday, May 7th. BTIG Research upped their price target on shares of RxSight from $61.00 to $72.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. Oppenheimer upped their price target on shares of RxSight from $61.00 to $72.00 and gave the stock an “outperform” rating in a report on Tuesday, May 7th. Needham & Company LLC upped their target price on shares of RxSight from $64.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Finally, Stifel Nicolaus cut their target price on shares of RxSight from $75.00 to $70.00 and set a “buy” rating for the company in a research report on Wednesday. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $65.00.

RxSight Price Performance

NASDAQ RXST traded down $2.06 during trading on Friday, hitting $47.72. 1,201,998 shares of the company’s stock traded hands, compared to its average volume of 518,686. The stock has a fifty day moving average of $58.40 and a two-hundred day moving average of $52.88. RxSight, Inc. has a 12-month low of $20.66 and a 12-month high of $66.54. The firm has a market cap of $1.77 billion, a P/E ratio of -37.87 and a beta of 1.20.

RxSight (NASDAQ:RXST) last posted its quarterly earnings results on Monday, May 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.08). RxSight had a negative net margin of 44.01% and a negative return on equity of 27.68%. The business had revenue of $29.51 million for the quarter, compared to analysts’ expectations of $27.56 million. During the same quarter in the previous year, the company earned ($0.42) earnings per share. The business’s quarterly revenue was up 68.7% on a year-over-year basis. As a group, analysts expect that RxSight, Inc. will post -0.77 earnings per share for the current fiscal year.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.